Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD) or Early Parkinson's Disease (PD)
Conditions
Interventions
Posiphen
Placebo
Locations
13
United States
New England Institute for Clinical Research
Stamford, Connecticut, United States
DeLand Clinical Research Unit
DeLand, Florida, United States
MD Clinical
Hallandale, Florida, United States
Homestead Associates in Research
Miami, Florida, United States
Ezy Medical Research Co.
Miami, Florida, United States
Conquest Research LLC
Winter Park, Florida, United States
Start Date
August 14, 2020
Primary Completion Date
August 16, 2021
Completion Date
January 31, 2022
Last Updated
February 28, 2023
NCT07187843
NCT07531732
NCT07290387
NCT04876339
NCT04650932
NCT06657768
Lead Sponsor
Annovis Bio Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions